Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy

Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy

Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy

Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy/Economic_IndiaTimes

Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy

In the intricate realm of biotech, Eyestem Research stands at the forefront, navigating a challenging path towards regulatory approval. The recently submitted Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) marks a pivotal moment for Eyestem’s therapy, Eyecyte-RPE. This groundbreaking treatment aims to address medium- and late-stage geographic atrophy, secondary to dry AMD, providing hope for patients.

Global Regulatory Landscape: A Balancing Act

Jogin Desai, CEO of Eyestem Research, sheds light on the complex dance with global regulatory agencies. Harmonization efforts are underway, with common technical documents acting as beacons across India, Australia, and Singapore. Desai emphasizes the importance of understanding each country’s unique regulatory nuances, be it India’s stringent input controls or Australia’s reliance on output controls.

The Rigorous Path to Clinical Stage: From Idea to Approval

Desai unravels the intricate lifecycle of a biotech company, detailing the rigorous journey from ideation to clinical-stage readiness. Animal trials, proof of concept, efficacy studies, and toxicity assessments constitute the arduous path. IND approval signifies a company’s maturity, signaling to investors and paving the way for impactful biotech solutions.

As Eyestem aims for IND approval, its CEO envisions a future where the company addresses not only dry AMD but also Parkinson’s and retinitis pigmentosa. With a commitment to affordability, Eyestem strives to revolutionize the cost paradigm in cell and gene therapies, offering a beacon of hope for patients globally.

In collaboration with renowned institutions like AIIMS in Delhi and LV Prasad Eye Institute, Eyestem Research propels regenerative therapies forward, setting new standards in ophthalmology. Beyond its immediate impact, this partnership hints at the transformative role Eyestem may play in the evolution of personalized and regenerative medicine.

Facebook
Twitter
LinkedIn
Telegram
WhatsApp
Email
Note: You have to fill-up above all respective field, then click below button for send your message